BOSTON SCIENTIFIC CORPORATION · Coronary Drug-Eluting Stent · First cleared Nov 2011
Total Reports
940
Reports (30d)
8
Active Signals
1
Open Recalls
0
What the reports describe · Claripulse analysis
Proximal Edge Dissection Post-Deployment
dissection, dissection occurred, located, synergy, lesion located
6
reports
Stent Crossing Failure in Tortuous Anatomy
located, procedure completed, stenosed target, encountered, completed
5
reports
In Vivo Stent Deformation During Advancement
onyx frontier, procedure involving, coronary drug, onyx, frontier
1
reports
Stent Flare Off Balloon Before Use
synergy, lesion located, shaft, completed, synergy drug
1
reports
Problem groupings are generated by Claripulse from report narrative text. They summarize what reporters wrote, not adjudicated root cause.
Detection
Evidence
The Vanishing Stent: A Rare Case Report of an Extracardiac Migration of a Coronary Stent.
Bhastana VJ, et al. · 2025
The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results
Robert Gil, et al. · Biomedicines · 2024
Citations indexed from PubMed.
Keep exploring
Perclose ProGlide
ABBOTT VASCULAR INC. · 24,504 reports
Perclose ProStyle
ABBOTT VASCULAR INC. · 19,336 reports
PERCLOSE
ABBOTT VASCULAR INC. · 9,890 reports
Angio-Seal
TERUMO MEDICAL CORPORATION · 6,417 reports
SYNERGY
BOSTON SCIENTIFIC CORPORATION · 5,991 reports
Resolute Onyx
MEDTRONIC, INC. · 4,467 reports
Claripulse monitors these devices weekly and detects anomalies using 6 statistical methods — spike, trend, changepoint, peer-outlier, and more. 1 active signal detected right now.
Get Early AccessUnderstanding this data
